NeuroPhage Pharmaceuticals Garners $12,400,000 Series B Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ad05020f-0c6a-45f6-9111-8c4c2cb69ca4&Preview=1 -
Date
3/1/2011 -
Company Name
NeuroPhage Pharmaceuticals -
Mailing Address
222 3rd St. Cambridge, MA 02142 -
Company Description
NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD. -
Website
http://www.neurophage.com -
Transaction Type
Venture Equity -
Transaction Amount
$12,400,000 -
Transaction Round
Series B -
Proceeds Purposes
The financing will be mostly directed to the IND-enabling activities in preparation of a Phase 1 clinical trial for NPT001, NeuroPhage’s lead product candidate for the treatment of Alzheimer’s disease, and include further work to expand the platform. -
M&A Terms
-
Venture Investor
bioMerieux -
Venture Investor
Undisclosed
